NASDAQ:ONCY Oncolytics Biotech (ONCY) Stock Price, News & Analysis $0.52 -0.01 (-2.09%) As of 11:15 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Oncolytics Biotech Stock (NASDAQ:ONCY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Oncolytics Biotech alerts:Sign Up Key Stats Today's Range$0.51▼$0.5350-Day Range$0.53▼$0.8852-Week Range$0.51▼$1.53Volume52,181 shsAverage Volume513,965 shsMarket Capitalization$44.59 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingBuy Company OverviewOncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Read More… Remove Ads Oncolytics Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks26th Percentile Overall ScoreONCY MarketRank™: Oncolytics Biotech scored higher than 26% of companies evaluated by MarketBeat, and ranked 723rd out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingOncolytics Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOncolytics Biotech has only been the subject of 3 research reports in the past 90 days.Read more about Oncolytics Biotech's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Oncolytics Biotech are expected to decrease in the coming year, from ($0.28) to ($0.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncolytics Biotech is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncolytics Biotech is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncolytics Biotech has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Oncolytics Biotech's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.51% of the float of Oncolytics Biotech has been sold short.Short Interest Ratio / Days to CoverOncolytics Biotech has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oncolytics Biotech has recently increased by 1.01%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOncolytics Biotech does not currently pay a dividend.Dividend GrowthOncolytics Biotech does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.51% of the float of Oncolytics Biotech has been sold short.Short Interest Ratio / Days to CoverOncolytics Biotech has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oncolytics Biotech has recently increased by 1.01%, indicating that investor sentiment is decreasing. News and Social Media0.6 / 5News SentimentN/A Search Interest8 people have searched for ONCY on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Oncolytics Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of -63% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Oncolytics Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.10% of the stock of Oncolytics Biotech is held by insiders.Percentage Held by InstitutionsOnly 6.82% of the stock of Oncolytics Biotech is held by institutions.Read more about Oncolytics Biotech's insider trading history. Receive ONCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address ONCY Stock News HeadlinesOncolytics price target lowered to $3 from $5 at MaximMarch 10, 2025 | markets.businessinsider.comOncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2024 Earnings Call TranscriptMarch 8, 2025 | msn.comTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth, your savings, and your retirement. When the dollar collapses, your savings could disappear overnight. With Trump threatening Russia with more sanctions, Russia is rushing to finalize their BRICS payment system aimed to destroy the U.S dollar.April 2, 2025 | Priority Gold (Ad)Oncolytics Biotech Inc. (ONCY) Q4 2024 Earnings Call TranscriptMarch 7, 2025 | seekingalpha.comOncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024March 7, 2025 | prnewswire.comWorld Cancer Day Sparks Big Questions About Pollution, Genetics, and InnovationFebruary 27, 2025 | baystreet.caUSA News Group: Oncology Breakthroughs: How Cancer Research Is Advancing in 2025February 27, 2025 | finanznachrichten.deOncolytics Biotech to Discuss 2024 Financial Results and Operational HighlightsFebruary 25, 2025 | tipranks.comSee More Headlines ONCY Stock Analysis - Frequently Asked Questions How have ONCY shares performed this year? Oncolytics Biotech's stock was trading at $0.9138 at the beginning of the year. Since then, ONCY stock has decreased by 43.5% and is now trading at $0.5160. View the best growth stocks for 2025 here. How were Oncolytics Biotech's earnings last quarter? Oncolytics Biotech Inc. (NASDAQ:ONCY) issued its quarterly earnings data on Friday, November, 3rd. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.07) by $0.03. How do I buy shares of Oncolytics Biotech? Shares of ONCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oncolytics Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oncolytics Biotech investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Pfizer (PFE), Meta Platforms (META), QUALCOMM (QCOM) and VBI Vaccines (VBIV). Company Calendar Last Earnings11/03/2023Today4/02/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ONCY CIK1129928 Webwww.oncolyticsbiotech.com Phone(403) 670-7377Fax403-283-0858Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$5.00 Low Stock Price Target$3.00 Potential Upside/Downside+659.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,560,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-141.15% Return on Assets-84.73% Debt Debt-to-Equity RatioN/A Current Ratio2.99 Quick Ratio2.99 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book1.95Miscellaneous Outstanding Shares86,422,000Free Float85,415,000Market Cap$45.54 million OptionableNot Optionable Beta1.18 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:ONCY) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.